Unearned vs. Earned Premium

In insurance, unearned and earned premiums refer to the portion of the premium that has not yet been used to cover the risk and the portion that has been used, respectively. Here's a definition and example of each:

  • Unearned premium: This is the portion of the premium that the insurer has received but has not yet earned because the coverage period has not yet ended. If the policyholder cancels the policy mid-term, the unearned premium will be returned to the policyholder. For example, if a policyholder pays $1,200 for an annual insurance policy but cancels the policy after six months, the unearned premium would be $600.
  • Earned premium: This is the portion of the premium that the insurer has earned because the coverage period has passed. If the policyholder cancels the policy mid-term, the earned premium will be kept by the insurer. For example, if a policyholder pays $1,200 for an annual insurance policy and cancels the policy after six months, the earned premium would be $600.

The unearned and earned premium are important for insurers to track to ensure they have enough funds to cover potential claims and expenses.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.